(Q43558334)

English

The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

0 references

author name string

Elisabeth J M Huijbers

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Julia Femel

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Karl Andersson

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hanna Björkelund

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Lars Hellman

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Anna-Karin Olsson

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

10 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

225-230

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Generation of therapeutic antibody responses against IgE through vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Control of allergic reactions in mice by an active anti-murine IL-4 immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Vaccination against the extra domain-B of fibronectin as a novel tumor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Fibronectins in vascular morphogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

UKCCCR guidelines for the welfare of animals in experimental neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Therapeutic vaccines against IgE-mediated allergies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Dendritic cells and interferon-mediated autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.010

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.11.010

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43558334&oldid=2100770972"